NovoCure (NVCR) shares plummeted 5.63% in pre-market trading on Thursday, despite the company reporting better-than-expected second-quarter 2025 results. The oncology company's stock decline reflects investor concerns over widening losses and future growth prospects.

For the quarter ended June 30, NovoCure reported revenue of $158.805 million, surpassing the FactSet consensus estimate of $154.2 million. The company also posted a narrower loss per share of $0.36, compared to analysts' expectations of a $0.38 loss. However, the net loss for the quarter widened to $40.139 million from $31 million in the same period last year, while operating income remained negative at -$39.521 million.

Despite beating estimates, the market's negative reaction suggests investors are focusing on the company's expanding losses and potential challenges in achieving profitability. NovoCure announced plans to submit PMAs (Pre-Market Approvals) to the FDA for pancreatic cancer in Q3 2025 and for NSCLC brain metastases, which could be potential growth drivers. However, these future catalysts appear insufficient to outweigh concerns about the company's current financial performance, leading to the sharp stock decline.